Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Lymphoma ; 59(4): 855-862, 2018 04.
Article in English | MEDLINE | ID: mdl-28728499

ABSTRACT

We analyzed ammonium levels and acute central nervous complications in adult patients receiving chemotherapy for acute lymphoblastic leukemia with or without asparaginase (l-asp). Twenty patients with a median age of 40.3 years were included. Ammonium-levels were measured during 88 chemotherapy cycles, 60 cycles (68%) with l-asp, and 28 cycles (32%) without l-asp. Ammonium was elevated in 87% of all l-asp containing cycles, with median ammonium levels of 169 µmol/l (interquartile range (IQR) 91-269 µmol/l). These values were higher when compared to ammonium levels at baseline (31.5 µmol/l, IQR 24-40 µmol/l, p < .001), and when compared to levels in cycles without l-asp (30 µmol/l, IQR 19-41 µmol/l, p < .001). Acute hyperammonemic encephalopathy was diagnosed in one patient, and encephalopathy for other reasons, but with hyperammonemia as a possible contributing factor in four patients. In conclusion, ammonium levels are elevated in all adult patients receiving l-asparaginase, but only some patients will present symptoms of encephalopathy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asparaginase/adverse effects , Hyperammonemia/complications , Neurotoxicity Syndromes/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adult , Ammonium Compounds/blood , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Asparaginase/therapeutic use , Female , Humans , Hyperammonemia/blood , Hyperammonemia/chemically induced , Male , Middle Aged , Neurotoxicity Syndromes/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...